NORD is pleased to announce the new video education session, "Evolving Treatment Approaches for Generalized Myasthenia Gravis (gMG) to Reduce Disease Burden and Improve Daily Living."After completing this session, participants should be better able to:
- Describe the impact of comorbidities on the burden of disease, quality of life (QoL), and selection of personalized treatment for patients with gMG.
- Define the profiles of patients who could benefit from emerging targeted treatment options for gMG based on the results of antibody testing, limitations of currently available treatment options, and comorbidities.
- Summarize the mechanism of action, efficacy, safety, and place in therapy of new and emerging targeted treatment options for gMG.
- Explain how current management of gMG with available immunomodulators, immunosuppressants, B-cell directed therapies, and complement inhibitors drives up direct and indirect healthcare costs and negatively impacts patients and caregivers QoL.
Attend the FREE continuing education session for clinicians
Tuesday, November 30, 2021
LIVE at 1:00 – 2:00pm ET, then available on-demand
www.neuroserieslive.com/app/login/
Topic Author
